Event-free survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta, Ja Hyeon Ku, Michal Kretkowski, Evanguelos Xylinas, Boris Alekseev, Dingwei Ye, Félix Guerrero-Ramos, Alberto Briganti, Girish S Kulkarni, Julia Brinkmann, Anna-Maria Calella, Rossano Cesari, Anthony Eccleston, Elisabete Michelon, Jennifer Vermette, Caimiao Wei, Gary D Steinberg
Nat Med 31(8) 2806-2814
Bacillus Calmette-Guérin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorable prognosis. Limited bladder-sparing therapeutic options exist, and no improvements to response durability have been observed in decades. CREST is a global, phase 3, randomized trial evaluating subcutaneous sasanlimab in combination with BCG-I+M (Arm A), sasanlimab in combination with BCG-I (Arm B) or BCG-I+M (Arm C) in BCG-naive high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS) for Arm A versus Arm C; key secondary endpoints were EFS (Arm B versus Arm C) and overall survival. Patients were randomized 1:1:1 to Arm A (N = 352), Arm B (N = 352) and Arm C (N = 351). The trial met its primary endpoint with a statistically significant and clinically meaningful prolongation of EFS (Arm A versus Arm C); hazard ratio, 0.68 (95% confidence interval: 0.49-0.94); one-sided P = 0.0095. The 36-month estimated EFS rates were 82.1% (Arm A) and 74.8% (Arm C). EFS benefit for Arm A versus Arm C was observed across prespecified subgroups, including carcinoma in situ (CIS) and T1. The safety profile of the combination was consistent with the known profiles. To our knowledge, sasanlimab is the first anti-PD-1 antibody to show a clinically meaningful prolongation of EFS when combined with BCG-I+M versus SOC in patients with BCG-naive high-risk NMIBC. Sasanlimab combined with BCG-I+M has the potential to redefine the treatment paradigm and clinical decision-making for patients with BCG-naive high-risk NMIBC. ClinicalTrials.gov identifier: NCT04165317 .
2 个 Figure · 4 个 KM 面板
Analysis of EFS in the intent-to-treat population for sasanlimab + BCG-I+M versus BCG-I+M and sasanlimab + BCG-I versus BCG-I+M. For EFS, an event was defined as the first of recurrence of high-grade disease, progression of disease, persistence of CIS (for patients with CIS at randomization) or death due to any cause. a , Kaplan–Meier estimates of EFS for sasanlimab + BCG-I+M versus BCG-I+M according to treatment arm in the intent-to-treat population. The dashed lines indicate EFS at 24 months and 36 months. b , Kaplan–Meier estimates of EFS for sasanlimab + BCG-I versus BCG-I+M according to treatment arm in the intent-to-treat population. The dashed lines indicate EFS at 24 months and 36 months.
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Analysis of OS in the intent-to-treat population. a , Kaplan–Meier estimates of OS for sasanlimab + BCG-I+M versus BCG-I+M. b , Kaplan–Meier estimates of OS for sasanlimab + BCG-I versus BCG-I+M.
Fig. 4 · Panel A
Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B
Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。